Showing results (1-10 of 112) with videos related to

Sort By:
Pageof 12
The Oncologist|July 31, 2016
Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and ManagementJonathan W Goldman, Melody A Mendenhall, Sarah R Rettinger
BMC Nephrology|August 22, 2018
PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case reportJonathan W Goldman, Basmah Abdalla, Melody A Mendenhall, et al.
Lab on a Chip|March 30, 2017
Biophysical isolation and identification of circulating tumor cellsJames Che, Victor Yu, Edward B Garon, et al.
Therapeutic Advances in Medical Oncology|February 1, 2018
Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and managementJohn Shen, Jason Chang, Melody Mendenhall, et al.
Seminars in Respiratory and Critical Care Medicine|May 26, 2020
Targeted Therapy for Non-Small Cell Lung CancerZorawar S Noor, Amy L Cummings, McKenna M Johnson, et al.
Clinical Lung Cancer|October 4, 2015
Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based ChemotherapyJonathan W Goldman, Peipei Shi, Martin Reck, et al.
Clinical Lung Cancer|August 1, 2024
Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping Mutations and Other MET-AlterationsMatthew S Lara, Jonathan W Riess, Jonathan W Goldman, et al.
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association|March 24, 2022
Facets of stigma, self-compassion, and health-related adjustment to lung cancer: A longitudinal studyTimothy J Williamson, Edward B Garon, Jenessa R Shapiro, et al.
Psychosomatic Medicine|March 4, 2024
Sleep Disturbance as a Mediator of Lung Cancer Stigma on Psychological Distress and Physical Symptom BurdenTimothy J Williamson, Edward B Garon, Michael R Irwin, et al.
The Lancet. Oncology|May 29, 2017
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trialNarek Shaverdian, Aaron E Lisberg, Krikor Bornazyan, et al.
Pageof 12